Sarepta Therapeutics (SRPT) EBIAT: 2012-2025
Historic EBIAT for Sarepta Therapeutics (SRPT) over the last 12 years, with Jun 2025 value amounting to -$447.5 million.
- Sarepta Therapeutics' EBIAT fell 7027.37% to -$447.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$248.4 million, marking a year-over-year decrease of 625.17%. This contributed to the annual value of $235.2 million for FY2024, which is 143.89% up from last year.
- Latest data reveals that Sarepta Therapeutics reported EBIAT of -$447.5 million as of Q2 2025, which was down 381.36% from $159.0 million recorded in Q4 2024.
- Sarepta Therapeutics' 5-year EBIAT high stood at $159.0 million for Q4 2024, and its period low was -$516.8 million during Q1 2023.
- In the last 3 years, Sarepta Therapeutics' EBIAT had a median value of $6.5 million in 2024 and averaged -$83.1 million.
- As far as peak fluctuations go, Sarepta Therapeutics' EBIAT skyrocketed by 248.37% in 2024, and later plummeted by 7,027.37% in 2025.
- Sarepta Therapeutics' EBIAT (Quarterly) stood at -$122.0 million in 2021, then climbed by 10.44% to -$109.2 million in 2022, then soared by 141.79% to $45.7 million in 2023, then spiked by 248.37% to $159.0 million in 2024, then tumbled by 7,027.37% to -$447.5 million in 2025.
- Its last three reported values are -$447.5 million in Q2 2025, $159.0 million for Q4 2024, and $33.6 million during Q3 2024.